Related Experiment Video
Updated: May 24, 2026

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart
Published on: January 7, 2019
Challenges for heart disease stem cell therapy
Jane Hoover-Plow1, Yanqing Gong
1Departmentof Cardiovascular Medicine, Joseph J Jacobs Center for Thrombosis and Vascular Biology, Cleveland Clinic Lerner Research Institute, Cleveland, OH 44195, USA. hooverj@ccf.org
Insights
Stem cell therapy shows promise for heart disease recovery after myocardial infarction (MI), but challenges remain. Optimizing stem cell identification, recruitment, and survival is key to improving cardiac function and patient outcomes.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Stem Cell Biology
Background:
- Cardiovascular diseases (CVDs) are a leading global cause of mortality.
- Stem cell therapy is an emerging strategy for cardiac repair post-myocardial infarction (MI).
- Current clinical trials show limited efficacy, with less than half reporting significant improvements in cardiac function.
Purpose of the Study:
- To provide an overview of stem cell therapy for CVD.
- To discuss key challenges hindering the optimization of stem cell therapy for heart disease.
- To highlight novel strategies being developed to enhance therapeutic efficacy.
Main Methods:
- Review of clinical trials using various stem cell sources (bone marrow, peripheral blood, umbilical cord blood).
- Analysis of approaches involving stem cell mobilization agents.
- Examination of strategies for improving stem cell survival and engraftment.
Main Results:
- Stem cell therapy for MI has yielded modest improvements in cardiac function in many trials.
- Commonly used stem cells include bone marrow, peripheral blood, and umbilical cord blood cells.
- Mobilizing agents alone have also been tested for recruiting endogenous stem cells.
Conclusions:
- Significant challenges exist in identifying, recruiting, and expanding autologous stem cells.
- Development of effective mobilizing and homing agents is crucial for enhancing stem cell recruitment.
- Improving the survival and engraftment of both endogenous and exogenous stem cells is essential for maximizing therapeutic benefits in CVD.
Abstract:
Cardiovascular diseases (CVDs) are the leading cause of death worldwide. The use of stem cells to improve recovery of the injured heart after myocardial infarction (MI) is an important emerging therapeutic strategy. However, recent reviews of clinical trials of stem cell therapy for MI and ischemic heart disease recovery report that less than half of the trials found only small improvements in cardiac function. In clinical trials, bone marrow, peripheral blood, or umbilical cord blood cells were used as the source of stem cells delivered by intracoronary infusion. Some trials administered only a stem cell mobilizing agent that recruits endogenous sources of stem cells. Important challenges to improve the effectiveness of stem cell therapy for CVD include: (1) improved identification, recruitment, and expansion of autologous stem cells; (2) identification of mobilizing and homing agents that increase recruitment; and (3) development of strategies to improve stem cell survival and engraftment of both endogenous and exogenous sources of stem cells. This review is an overview of stem cell therapy for CVD and discusses the challenges these three areas present for maximum optimization of the efficacy of stem cell therapy for heart disease, and new strategies in progress.
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Stem Cell Culture
iPS Cell Differentiation
Embryonic Stem Cells
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
Mesenchymal Stem Cells

